According to the Zhitong Finance APP, Yongtai Biology-B (06978) rose nearly 20% in the morning session, up 15.94% as of press time, at HK$2.91, with a turnover of 2.9999 million Hong Kong dollars.

On the news front, the new version of the pharmaceutical catalog will be officially implemented nationwide on January 1, 2025. It is reported that four million yuan CAR-T cell therapies do not appear in this directory list, as pricing remains a commercial constraint due to the continued reliance on imported raw materials. Yongtai Biology has developed a plasmid, viral vector production and purification technology platform for cell genetic modification, enabling stable mass production of a large number of clinically standardized lentiviral vectors for various gene transduction cell preparations (CAR-T and TCR-T). By producing lentiviral vectors in-house, it can reduce production costs, accelerate research and development progress, and increase product competitive advantages.

Public information shows that Yongtai Biology is researching cell immunotherapy covering multiple technology paths such as AAL, CAR-T, and TCR-T. The company's core product EAL is a multi-target cell immunotherapy product with over a decade of track record in clinical applications for cancer treatment. The group plans to advance the declaration, production, and quality verification of EAL Phase II clinical trials to expedite registration and obtain the necessary data, while also advancing future commercial layout.